Protocol Ledger

NCT06559150 · Phase II · RECRUITING

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Interventional Phase II clinical trial protocol NCT06559150 sponsored by Merck & Co. in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-11 Enrollment: 284 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06559150
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)284 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06559150
Protocol FieldVerified Registry Value
NCT IdentifierNCT06559150
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment284 participants (ESTIMATED)
Registered Start Date2024-09-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06559150
Hospital Research SiteLocationSite Profile
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
MedStar Georgetown University HospitalWashington D.C, DCOpen Hospital Dossier ->
University of MiamiMiami, FLOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI